33 results
8-K
EX-99.2
f91xxk
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
h0f6ubxdco 6yaie3frh
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
d70qn45etvju
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-99.2
qak od1ut4p0
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-10.1
lolmrtwp6hv
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
EX-1.1
7faqv5rdr29a
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
8-K
EX-99.1
dkflflv42zd
12 Aug 19
Other Events
7:05am
8-K
EX-1.1
t9becedd v83dz
26 Mar 19
Entry into a Material Definitive Agreement
6:07am